Report : Europe Epirubicin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Dosage (10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial), Application (Breast Cancer, Liver Cancer, Bladder Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
At 3.4% CAGR, the Europe Epirubicin Market is speculated to be worth US$ 62,495.08 thousand by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe epirubicin market was valued at US$ 51,079.61 thousand in 2022 and is expected to reach US$ 62,495.08 thousand by 2028, registering an annual growth rate of 3.4% from 2022 to 2028. Rising prevalence of cancer and increasing awareness regarding cancer are the critical factors attributed to the market expansion.
Epirubicin is an anticancer drug that falls under the category of anthracyclines and is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy has removed most of them. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. The percentage of people who get liver cancer has been rising for several decades. Liver cancer very common in several parts of the region. Hence, the rising prevalence of cancer cases is driving the epirubicin market across the region.
On the contrary, elevated risk of adverse effects due to epirubicin hurdles the growth of Europe epirubicin market.
- Based on dosage, the Europe epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held 38.7% market share in 2022, amassing US$ 19,786.95 thousand. It is projected to garner US$ 24,519.52 thousand by 2028 to expand at 3.6% CAGR during 2022–2028.
- Based on application, the Europe epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held 71.4% market share in 2022, amassing US$ 36,479.80 thousand. It is projected to garner US$ 44,971.06 thousand by 2028 to expand at 3.5% CAGR during 2022–2028.
- Based on distribution channel, the Europe epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 59.8% market share in 2022, amassing US$ 30,544.70 thousand. It is projected to garner US$ 38,165.75 thousand by 2028 to expand at 3.8% CAGR during 2022–2028.
- Based on country, the Europe epirubicin market has been categorized into the UK, Germany, France, Italy, Russia, and rest of Europe. Our regional analysis states that the UK captured 25.4% market share in 2022. It was assessed at US$ 13,150.42 thousand in 2022 and is likely to hit US$ 16,651.78 thousand by 2028, exhibiting a CAGR of 4.0% during the forecast period.
Key players dominating the Europe epirubicin market are Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. among others.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com